ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
The last earnings update was 68 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
ANI Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
ANI Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
ANI Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
ANI Pharmaceuticals's revenue is expected to grow by 10.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
ANI Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
3/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
ANI Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
ANI Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
ANI Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
ANI Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is not covered by short term assets, assets are 0.8x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Arthur S. Przybyl has been the Chief Executive Officer and President of ANI Pharmaceuticals, Inc. since June 19, 2013. Mr. Przybyl's career includes several management positions in both pharmaceutical and medical device companies over the last twenty-five years. Mr. Przybyl served as the Chief Executive Officer of Akorn Inc. from February 2003 to January 2009 and its President from September 23, 2002 to January 2009. Mr. Przybyl served as an Interim Chief Executive Officer of Akorn Inc., from February 17, 2003 to June 9, 2003 and also served as its Chief Operating Officer from September 23, 2002 to February 2003. He joined Akorn Inc., in August 2002 as Senior Vice President of Sales and Marketing. Mr. Przybyl served as Chief Executive Officer and President of Hearing Innovations Inc. Prior to that, he served as President and Chief Operating Officer of Bioject Inc. Mr. Przybyl has been Director of ANI Pharmaceuticals, Inc. since June 2013. He served as Director of Novadaq Technologies Inc., until July 2004. He served as a Director of Akorn Inc., from November 2003 to January 2009.
Arthur's compensation has been consistent with company performance over the past year, both up more than 20%.
Arthur's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the ANI Pharmaceuticals management team is about average.
CFO & VP of Finance
Senior Vice President of Operations & Product Development
Senior Vice President of Business Development & Specialty Sales
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the ANI Pharmaceuticals board of directors is about average.
Board of Directors
Chairman of The Board
Who owns this company?
Recent Insider Trading
ANI Pharmaceuticals individual insiders have sold more shares than they have bought in the past 3 months.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.